期刊文献+

阿仑膦酸钠对甲亢患者骨密度的影响 被引量:4

Influence of alendronate sodium on bone mineral density in patients with hyperthyroidism
暂未订购
导出
摘要 目的探讨阿仑膦酸钠对20~40岁甲亢患者骨密度的影响。方法选择正常健康志愿者30例作为正常对照组(B组)。76例甲亢患者随机分为2组:A1组38例,服抗甲亢药;A2组38例,在服抗甲亢药的基础上加服阿仑膦酸钠5 mg/d。2组共服药12个月。结果 A2组腰椎、股骨颈及大粗隆的骨密度均明显升高(P均〈0.05),其中腰椎骨密度治疗前为(0.91±0.09)g/cm2,治疗后12个月为(1.11±0.07)g/cm2,增加率30.6%,明显高于A1组(P〈0.05)。12个月治疗总有效率A2组为61.2%,显著高于A1组的31.6%(P〈0.05)。患者无严重不良反应。结论阿仑膦酸钠能明显提高甲亢患者的骨密度,不良反应少。 Objective It is to approach the influence of alendronate sodium on bone mineral density in patients with hyperthyroidism whose ages were from 20 to 40 years old.Methods 30 healthy volunteers were chosen as normal control group.76 patients with hyperthyroidism were randomly divided into two groups.38 cases were in group A1 and treated with drugs which were treated for hyperthyroidism,and the other 38 cases were in group A2 and treated with alendronate sodium 5 mg/d on the base of the treatment of group A1.Both the two groups were treated for twelve months.Results Bone mineral density of lumbar vertebra,femoral neck,and greater trochanter in group A2 increased obviously(P0.05).Among the total,bone mineral density of lumbar vertebra before treatment was(0.91±0.09)g/cm2 and that after treatment for 12 months was(1.11±0.07)g/cm2,and the increased rate was 30.6%,which was obviously higher than that in group A1(P0.05).No severe untoward reaction was observed in both the two groups.Conclusion Alendronate can obviously heighten the bone mineral density of the patients with hyperthyroidism without severe untoward reaction.
出处 《现代中西医结合杂志》 CAS 2010年第20期2471-2472,2600,共3页 Modern Journal of Integrated Traditional Chinese and Western Medicine
基金 广东省医学科研基金资助项目(A2009268) 广州市中医药中西医结合科研基金资助项目(2005A045)
关键词 阿仑膦酸钠 骨质疏松症 骨密度 甲亢 alendronate osteoporosis bone mineral density hyperthyroidism
  • 相关文献

参考文献8

  • 1Allain TJ,McGiegorn AM.Thyroid hormones and bone[J].Endocrinol,1993,139(1):1218.
  • 2Body JJ,Demeester-Mirkine N,Borkowski A,et al.Calcitonin deficiency in primary hypothyroidism[J].J Clin Endocrinol Metab,1986,62(4):700-703.
  • 3孟迅吾,朱汉民,刘建立,张绍芬,夏维波,陈小平,张忠兰,朱芝玲,余卫,陈淑英,黄敏丽,邢小平,朱晓颖,周学瀛,甘洁民.阿伦膦酸钠防治原发性骨质疏松症[J].中华内分泌代谢杂志,1998,14(5):295-298. 被引量:28
  • 4Rosen HN,Sullivan EK,Middlebrooks L,et al.Parenteral pamidronate prevents thyroid horone induced bone loss in rats[J].J Bone Mineral Res,1993,8(3):1255-1261.
  • 5Ongphiphadhanakul B,Alex S,Bravernan L,et al.Intermittent et-idronate administ ration prevents the thyroid hormone induced decrease in bone mineral density in the rat(Abstract).Clin Res,1992,40(1):165A.
  • 6Rosen HN,Moses AC,Gundberg C,et al.Therapy wit h parenteral anidronate prevents thyroid hormone induced bone turnover in humans[J].J Clin Endocrinol Metab,1993,77(8):664-669.
  • 7Lupoli G,Nuzzo V,Di Carlo C,et al.Effect s of alendronate on bone loss in pre and postmenopausal hyperthyroid women treated with met himazole[J].Gynecol Endocrinol,1996,10(5):343-348.
  • 8李亚伟,吕涛.甲亢治疗前、后骨代谢的临床观察[J].中国骨质疏松杂志,2003,9(3):253-254. 被引量:10

二级参考文献5

  • 1陈芳 尤传一 甘洁尼等.甲状腺机能亢进症性骨质疏松与骨代谢生化指标的关系[A]..上海市第一届骨质疏松学术会议论文集[C].,2000.226-229.
  • 2Kiahimoto T, Taga T, Akira S. Cytokine aignal transduction. Cell, 1994,76:253.
  • 3Allain TJ, McGregor AM. Thyroid hormones and bone. Endocrinol, 1993,139:9-18.
  • 4孟迅吾,中华内科杂志,1989年,28卷,95页
  • 5徐浩,EichS.,H.甲亢患者骨密度和血清骨代谢指标的变化[J].中华内分泌代谢杂志,1998,14(4):244-247. 被引量:29

共引文献35

同被引文献37

引证文献4

二级引证文献20

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部